INTS Stock Summary and Trading Ideas (Intensity Therapeutics | NASDAQ:INTS)

Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.

Intensity Therapeutics trades on the NASDAQ stock market under the symbol INTS.

As of September 4, 2026, INTS stock price climbed to $4.10 with 3,427 million shares trading.

INTS has a beta of 0.86, meaning it tends to be less sensitive to market movements. INTS has a correlation of 0.01 to the broad based SPY ETF.

INTS has a market cap of $13.39 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, INTS traded as high as $286.00 and as low as $3.51.

The top ETF exchange traded funds that INTS belongs to (by Net Assets): VXF.

INTS has underperformed the market in the last year with a price return of -39.2% while the SPY ETF gained +20.8%. INTS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +2.0% and -16.0%, respectively, while the SPY returned +2.4% and +1.0%, respectively.

INTS support price is $3.75 and resistance is $4.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INTS shares will trade within this expected range on the day.